Enhanced Nanomedicinal Compositions for Breast Cancer Treatment

Publication ID: 24-11857639_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Nanomedicinal Compositions for Breast Cancer Treatment,” Published Technical Disclosure No. 24-11857639_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857639_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,639.

Summary of the Inventive Concept

This inventive concept improves the original nanomedicinal composition for breast cancer treatment by introducing functionalized nanocarriers, sustained release mechanisms, and immunomodulatory agents, enhancing selective uptake, efficacy, and safety.

Background and Problem Solved

The original patent disclosed a nanomedicinal composition for breast cancer treatment, but it had limitations in terms of selective uptake, efficacy, and toxicity. The new inventive concept addresses these limitations by incorporating advanced nanocarrier designs, controlled release mechanisms, and immunomodulatory agents.

Detailed Description of the Inventive Concept

The enhanced nanomedicinal composition comprises a nanocarrier with a porous silicate matrix and particles of a magnetic ferrite, functionalized with a targeting moiety to enhance selective uptake by cancer cells. The nanocarrier is designed to release the pharmaceutical agent mixture in a sustained manner over a prolonged period, ensuring optimal efficacy. Additionally, the composition includes an immunomodulatory agent to enhance the immune response against cancer cells. The system can also be adapted for monitoring the efficacy of the treatment and reducing toxicity in healthy tissues.

Novelty and Inventive Step

The new inventive concept introduces several novel features, including functionalized nanocarriers, sustained release mechanisms, and immunomodulatory agents, which are not present in the original patent. These advancements provide a significant improvement in selective uptake, efficacy, and safety, making the new inventive concept non-obvious and innovative.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include varying the type of targeting moiety, adjusting the sustained release profile, or incorporating different immunomodulatory agents. Additionally, the system could be adapted for treating other types of cancer or diseases.

Potential Commercial Applications and Market

The enhanced nanomedicinal composition has significant commercial potential in the breast cancer treatment market, with potential applications in personalized medicine, targeted therapies, and immunotherapy. The market for breast cancer treatment is projected to grow significantly in the coming years, and this inventive concept is well-positioned to capitalize on this trend.

CPC Classifications

SectionClassGroup
A A61 A61K47/6923
A A61 A61K31/138
A A61 A61K31/282
A A61 A61K33/243
A A61 A61K47/10
A A61 A61K2121/00
A A61 A61K2800/47
B B82 B82Y5/00
B B82 B82Y25/00
B B82 B82Y30/00
B B82 B82Y40/00

Field of Art

Nanomedicine and targeted drug delivery systems for cancer treatment, specifically focusing on nanocarrier design, pharmaceutical compositions, and cancer therapeutic strategies

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with expertise in nanotechnology, pharmaceutical sciences, and oncology, possessing advanced degrees in chemistry, materials science, or biomedical engineering, with knowledge of nanocarrier functionalization, drug delivery mechanisms, and cancer treatment approaches

Obviousness Rationale

A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's nanomedicinal composition, utilizing standard techniques in nanocarrier design and cancer treatment to enhance selective targeting, sustained release, and therapeutic efficacy. The proposed modifications align with established strategies in nanomedicine for improving drug delivery and treatment outcomes. These variations would be considered routine optimization and combinatorial approaches well within the capabilities of a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
Nanocarrier with mesosilicalite and magnetic ferrite particles
PTD Variation
Functionalization of nanocarrier with targeting moiety to enhance selective cancer cell uptake
Obviousness Reasoning
Targeting ligand modification is a known technique in nanomedicine for improving drug delivery specificity, representing a predictable design choice for enhancing therapeutic targeting
Source Patent Element
Pharmaceutical composition for breast cancer treatment
PTD Variation
Incorporation of immunomodulatory agents to enhance immune response
Obviousness Reasoning
Combining therapeutic agents with immunomodulatory components is a standard approach in cancer treatment to improve overall therapeutic efficacy, representing a finite and predictable solution
Source Patent Element
Nanocarrier with porous silicate matrix containing pharmaceutical agents
PTD Variation
Sustained release mechanism designed to control drug delivery over prolonged periods
Obviousness Reasoning
Controlled release strategies are well-established in drug delivery systems, representing a known technique for optimizing therapeutic performance and minimizing side effects
Source Patent Element
Magnetic ferrite particles in nanocarrier
PTD Variation
Diagnostic agent release mechanism responsive to tumor microenvironment changes
Obviousness Reasoning
Integrating diagnostic capabilities with therapeutic nanocarriers is a predictable innovation in personalized medicine, utilizing the inherent properties of magnetic nanoparticles
Source Patent Element
Nanomedicinal composition for cancer treatment
PTD Variation
Toxicity reduction through selective drug release mechanisms
Obviousness Reasoning
Minimizing systemic toxicity is a standard design goal in nanomedicine, representing an obvious optimization strategy for improving treatment safety
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857639 and the disclosed variations, a person having ordinary skill in the art would find the proposed nanomedicinal composition modifications obvious and predictable. The PTD demonstrates that the claimed enhancements represent routine optimization and combinatorial approaches within the established knowledge of nanomedicine and cancer treatment strategies, thereby rendering potential patent claims obvious and anticipatable as prior art.

Original Patent Information

Patent NumberUS 11,857,639
TitleMethod for treating breast cancer
Assignee(s)Imam Abdulrahman Bin Faisal University